ID   INT-MEL-12
AC   CVCL_A648
SY   Me10538; ME10538; ME 10538; Me 10538; Me1053/8; 10538
DR   cancercelllines; CVCL_A648
DR   Cosmic; 889006
DR   Cosmic; 928710
DR   Cosmic; 1211153
DR   GEO; GSM1403082
DR   GEO; GSM1403083
DR   GEO; GSM1403084
DR   Wikidata; Q54897757
RX   DOI=10.1007/0-306-46872-7_16;
RX   PubMed=2469723;
RX   PubMed=2776368;
RX   PubMed=7520026;
RX   PubMed=8459226;
RX   PubMed=8980186;
RX   PubMed=9354451;
RX   PubMed=9725211;
RX   PubMed=9973437;
RX   PubMed=15048078;
RX   PubMed=22383533;
RX   PubMed=25576923;
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=9354451).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=15048078; PubMed=22383533).
CC   Sequence variation: Mutation; HGNC; HGNC:1773; CDK4; Simple; p.Arg24Cys (c.70C>T); ClinVar=VCV000016928; Zygosity=Heterozygous (PubMed=22383533).
CC   Sequence variation: Mutation; HGNC; HGNC:9612; PTK2B; Simple; p.Gly414Val (c.1241G>T); Zygosity=Heterozygous (PubMed=22383533).
CC   Misspelling: ME10358; Note=Occasionally.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_C690 ! LCL10538
SX   Female
AG   56Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 19-12-24; Version: 19
//
RX   DOI=10.1007/0-306-46872-7_16;
RA   Anichini A., Mortarini R., Vegetti C., Molla A., Borri A., Parmiani G.;
RT   "Melanoma: the Milan melanoma cell lines.";
RL   (In book chapter) Human cell culture. Vol. 1. Cancer cell lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.283-292; Kluwer Academic Publishers; New York; USA (1999).
//
RX   PubMed=2469723; DOI=10.4049/jimmunol.142.10.3692;
RA   Anichini A., Mazzocchi A., Fossati G., Parmiani G.;
RT   "Cytotoxic T lymphocyte clones from peripheral blood and from tumor
RT   site detect intratumor heterogeneity of melanoma cells. Analysis of
RT   specificity and mechanisms of interaction.";
RL   J. Immunol. 142:3692-3701(1989).
//
RX   PubMed=2776368; DOI=10.1007/BF01753674;
RA   Larizza L., Doneda L., Rodolfo M., Fossati G.;
RT   "High incidence of chromosomal lesions involving C-heterochromatin in
RT   four human melanoma lines.";
RL   Clin. Exp. Metastasis 7:633-644(1989).
//
RX   PubMed=7520026; DOI=10.1002/ijc.2910580413;
RA   Hersey P., Si Z.-Y., Smith M.J., Thomas W.D.;
RT   "Expression of the co-stimulatory molecule B7 on melanoma cells.";
RL   Int. J. Cancer 58:527-532(1994).
//
RX   PubMed=8459226; DOI=10.1084/jem.177.4.989; PMCID=PMC2190978;
RA   Anichini A., Maccalli C., Mortarini R., Salvi S., Mazzocchi A.,
RA   Squarcina P., Herlyn M., Parmiani G.;
RT   "Melanoma cells and normal melanocytes share antigens recognized by
RT   HLA-A2-restricted cytotoxic T cell clones from melanoma patients.";
RL   J. Exp. Med. 177:989-998(1993).
//
RX   PubMed=8980186; DOI=10.1002/(SICI)1097-0215(19961211)68:6<795::AID-IJC18>3.0.CO;2-#;
RA   Thomas W.D., Smith M.J., Si Z.-Y., Hersey P.;
RT   "Expression of the co-stimulatory molecule CD40 on melanoma cells.";
RL   Int. J. Cancer 68:795-801(1996).
//
RX   PubMed=9354451;
RA   Castellano M., Pollock P.M., Walters M.K., Sparrow L.E., Down L.M.,
RA   Gabrielli B.G., Parsons P.G., Hayward N.K.;
RT   "CDKN2A/p16 is inactivated in most melanoma cell lines.";
RL   Cancer Res. 57:4868-4875(1997).
//
RX   PubMed=9725211; DOI=10.4049/jimmunol.161.5.2195;
RA   Thomas W.D., Hersey P.;
RT   "TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in
RT   Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of
RT   target cells.";
RL   J. Immunol. 161:2195-2200(1998).
//
RX   PubMed=9973437; DOI=10.4049/jimmunol.162.3.1739;
RA   Castelli C., Tarsini P., Mazzocchi A., Rini F., Rivoltini L.,
RA   Ravagnani F., Gallino F., Belli F., Parmiani G.;
RT   "Novel HLA-Cw8-restricted T cell epitopes derived from
RT   tyrosinase-related protein-2 and gp100 melanoma antigens.";
RL   J. Immunol. 162:1739-1748(1999).
//
RX   PubMed=15048078; DOI=10.1038/sj.onc.1207563;
RA   Pavey S., Johansson P., Packer L., Taylor J., Stark M.S., Pollock P.M.,
RA   Walker G.J., Boyle G.M., Harper U., Cozzi S.-J., Hansen K., Yudt L.,
RA   Schmidt C., Hersey P., Ellem K.A.O., O'Rourke M.G.E., Parsons P.G.,
RA   Meltzer P.S., Ringner M., Hayward N.K.;
RT   "Microarray expression profiling in melanoma reveals a BRAF mutation
RT   signature.";
RL   Oncogene 23:4060-4067(2004).
//
RX   PubMed=22383533; DOI=10.1158/1535-7163.MCT-11-0676;
RA   Dutton-Regester K., Irwin D., Hunt P., Aoude L.G., Tembe V.,
RA   Pupo G.M., Lanagan C., Carter C.D., O'Connor L., O'Rourke M.,
RA   Scolyer R.A., Mann G.J., Schmidt C.W., Herington A., Hayward N.K.;
RT   "A high-throughput panel for identifying clinically relevant mutation
RT   profiles in melanoma.";
RL   Mol. Cancer Ther. 11:888-897(2012).
//
RX   PubMed=25576923; DOI=10.18632/oncotarget.2995; PMCID=PMC4413617;
RA   Loria R., Bon G., Perotti V., Gallo E., Bersani I., Baldassari P.,
RA   Porru M., Leonetti C., Di Carlo S., Visca P., Brizzi M.F.,
RA   Anichini A., Mortarini R., Falcioni R.;
RT   "Sema6A and Mical1 control cell growth and survival of BRAFV600E human
RT   melanoma cells.";
RL   Oncotarget 6:2779-2793(2015).
//